Cabaletta Bio (NASDAQ:CABA) has received positive analyst ratings in the last quarter, with 9 bullish and 4 somewhat bullish ratings, and no negative ratings. The average 12-month price target for CABA is $30.78, which is a 41.52% increase from the previous target of $21.75. The high target is $50.00 and the low target is $17.00. Analysts typically review stocks quarterly or after major company updates, basing their predictions on financial performance and company risk.